Older Patients with Atopic Dermatitis Show More Pronounced Early Clinical Improvement with Tralokinumab: A Single-Center Retrospective Real-World Study
Abstract
Background/Objective: Tralokinumab, a monoclonal antibody targeting interleukin-13, is an effective treatment for atopic dermatitis (AD). However, real-world data on age-related differences in clinical responses, particularly among older patients, remain limited. We compared early improvements in pruritus and skin lesions, as well as effectiveness, safety, and treatment persistence of tralokinumab, between older patients aged ≥ 70 and
Fields of Study & Subjects
Dermatology and Skin Diseases
Psoriasis: Treatment and Pathogenesis
Asthma and respiratory diseases
Publication details
- Journal / source
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Volume
- 15
- Issue
- 3
- Pages
- 1117–1117
- Publication date
- 30 January 2026
- Language
- EN